Today, we’ve launched an updated BiomarkerCommons.org website. We’ve kept the clean page style and introduce larger, easier-to-read fonts and a new layout optimized for all your mobile devices.
Biomarker Commons launched three-and-a-half years ago with an ambitious goal: curate the growing biomarker industry and track the discovery, development and use of biomarkers. Our business plan was simple: support the site with advertising revenue. Not surprisingly, given the changes to the media industry over the last few years, that plan hasn’t worked out.
Biomarker Commons launched just over three years ago with the goal of aggregating the latest biomarker and personalized medicine news.
Now, we really need your feedback. We’ve got 8 simple questions that should take you less than 5 minutes to complete. Please let us know how we’ve been doing and what we can do to improve our service.
The National Institutes of Health announced last week that the National Institute of Neurological Disorders and Stroke (NINDS) on behalf of the NIH Common Fund Program on Extracellular RNA Communication will support studies that promote the identification and validation of extracellular RNA (exRNA)-based biomarkers readily available from human body fluids and to facilitate the assessment and qualification of biomarkers for their utility in the clinical setting.
Tegal Corporation recently announced that it would acquire CollabRx, Inc., a privately held technology company that uses information technology to inform personalized cancer treatment planning by combining knowledge of new therapies with expert insight. The acquisition was completed yesterday (July 16th, 2012).
Companion Diagnostics Budgets Exceed $1 Million as Companies Build Personalized Medicine into Drug Development Strategy
As the drug discovery paradigm shifts away from mass-marketed products toward targeted treatments and the life sciences industry adjusts to an increasingly payer-driven environment, precision medicine is emerging as a critical asset in the clinical development strategy. Biomarkers and companion diagnostics offer companies the ability to target a specific patient population with increased efficacy, accelerated regulatory approval and better reimbursement. Consulting firm Cutting Edge Information reports that almost 50% of drug discovery companies spend between $1 and $5 million to develop targeted therapeutic technologies that increase the effectiveness of drugs in development. Another 33% of companies invest half to a fifth as much ($500,000 to $1 million), and only a few report companion diagnostics budgets under $500,000.
Presentations from the Covance Symposium Recent Advances in Biomarkers of Parkinson’s Disease at the 2011 Society for Neuroscience Conference is now available to watch on the Covance website. Listen to discussions regarding recent innovations in imaging, genomic, proteomic, and fluid biomarkers of Parkinson’s disease and their potential application to the clinic.